DUBLIN, May 8, 2020 /PRNewswire/ --
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR
IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH
JURISDICTION
Allergan plc (NYSE: AGN) ("Allergan") announced that
AbbVie has now completed the acquisition of Allergan pursuant to a
scheme of arrangement under Chapter 1 of Part 9 of the Irish
Companies Act 2014 (the "Scheme"), which became effective
earlier today, May 8, 2020.
Payment to Allergan shareholders of the consideration to which
they are entitled under the Scheme will be made within 14 days in
accordance with the terms of the Scheme and is expected to commence
as soon as practicable.
ABOUT ALLERGAN
Allergan is a global pharmaceutical leader. Allergan is focused
on developing, manufacturing and commercializing branded
pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world. Allergan markets a
portfolio of leading brands and best-in-class products primarily
focused on four key therapeutic areas including medical aesthetics,
eye care, central nervous system and gastroenterology. Allergan has
operations in more than 100 countries.
ENQUIRIES
|
|
|
|
Allergan
|
|
|
|
Media:
|
Lisa
Brown
|
+1 862 261
7320
|
|
|
|
Investors:
|
Manisha Narasimhan,
PhD
|
+1 862 261
7162
|
FORWARD-LOOKING STATEMENTS
This announcement contains certain forward-looking statements,
including with respect to the acquisition involving AbbVie and
Allergan and AbbVie's, Allergan's and/or the combined group's
estimated or anticipated future business, performance and results
of operations and financial condition, including estimates,
forecasts, targets and plans for AbbVie and, following the
acquisition, if completed, the combined group. The words "believe,"
"expect," "anticipate," "project" and similar expressions, among
others, generally identify forward-looking statements. These
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Such risks and
uncertainties include, but are not limited to, failure to realize
the expected benefits of the pending acquisition, failure to
promptly and effectively integrate Allergan's businesses, general
economic and business conditions that affect the combined companies
following the consummation of the pending acquisition, changes in
global, political, economic, business, competitive, market and
regulatory forces, future exchange and interest rates, changes in
tax laws, regulations, rates and policies, future business
acquisitions or disposals and competitive developments. These
forward-looking statements are based on numerous assumptions and
assessments made in light of AbbVie's or, as the case may be,
Allergan's experience and perception of historical trends, current
conditions, business strategies, operating environment, future
developments and other factors it believes appropriate. By their
nature, forward-looking statements involve known and unknown risks
and uncertainties because they relate to events and depend on
circumstances that will occur in the future. The factors described
in the context of such forward-looking statements in this
announcement could cause AbbVie's plans with respect to Allergan or
AbbVie's or Allergan's actual results, performance or achievements,
industry results and developments to differ materially from those
expressed in or implied by such forward-looking statements.
Although it is believed that the expectations reflected in such
forward-looking statements are reasonable, no assurance can be
given that such expectations will prove to have been correct and
persons reading this announcement are therefore cautioned not to
place undue reliance on these forward-looking statements which
speak only as of the date of this announcement. Additional
information about economic, competitive, governmental,
technological and other factors that may affect AbbVie or Allergan
is set forth in AbbVie's and Allergan's periodic public filings
with the U.S. Securities and Exchange Commission, including, but
not limited to, AbbVie's and Allergan's Annual Report on Form 10-K
for the year ended December 31, 2019,
and, from time to time, AbbVie's and Allergan's other investor
communications, in each case, the contents of which are not
incorporated by reference into, nor do they form part of, this
announcement.
Any forward-looking statements in this announcement are based
upon information available to AbbVie, Allergan and/or their
respective board of directors, as the case may be, as of the date
of this announcement and, while believed to be true when made, may
ultimately prove to be incorrect. Subject to any obligations under
applicable law, none of AbbVie, Allergan or any member of their
respective board of directors undertakes any obligation to update
any forward-looking statement whether as a result of new
information, future developments or otherwise, or to conform any
forward-looking statement to actual results, future events, or to
changes in expectations. All subsequent written and oral
forward-looking statements attributable to AbbVie, Allergan or
their respective board of directors or any person acting on behalf
of any of them are expressly qualified in their entirety by this
paragraph.
Statement Required by the Irish Takeover Rules
The Allergan directors accept responsibility for the information
contained in this announcement. To the best of the knowledge
and belief of the Allergan directors (who have taken all reasonable
care to ensure such is the case), the information contained in this
announcement for which they accept responsibility is in accordance
with the facts and does not omit anything likely to affect the
import of such information.
General
The release, publication or distribution of this announcement in
or into certain jurisdictions may be restricted by the laws of
those jurisdictions (the "Restricted Jurisdictions"). Accordingly,
copies of this announcement and all other documents relating to the
acquisition are not being, and must not be, released, published,
mailed or otherwise forwarded, distributed or sent in, into or from
any Restricted Jurisdictions. Persons receiving such documents
(including, without limitation, nominees, trustees and custodians)
should observe these restrictions. Failure to do so may constitute
a violation of the securities laws of any such jurisdiction. To the
fullest extent permitted by applicable law, the companies involved
in the acquisition disclaim any responsibility or liability for the
violations of any such restrictions by any person.
A copy of this announcement will be available, free of charge
(subject to certain restrictions relating to persons resident in
Restricted Jurisdictions) on the Allergan website at
www.allergan.com. Neither the content of such website nor the
content of any other website accessible from hyperlinks on such
website is incorporated into, or forms part of, this
announcement.
This announcement has been prepared for the purpose of complying
with the laws of Ireland and the
Takeover Rules and the information disclosed may not be the same as
that which would have been disclosed if this announcement had been
prepared in accordance with the laws of jurisdictions outside of
Ireland.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/abbvie-inc-completes-acquisition-of-allergan-plc-301055951.html
SOURCE Allergan plc